Journal: Bioengineering & Translational Medicine

Article Title: Human induced pluripotent stem cells ‐derived liver organoids grown on a Biomimesys® hyaluronic acid‐based hydroscaffold as a new model for studying human lipoprotein metabolism

doi: 10.1002/btm2.10659

Figure Lengend Snippet: Three‐dimensional differentiation protocol of hiPSC in Biomimesys®.

Article Snippet: D13 , , RPMI 1640 medium (Life Technologies) + B27 (with insulin) (Life Technologies) , HGF (100 ng/ml) (Miltenyi).

Techniques: Incubation

Journal: bioRxiv

Article Title: Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators

doi: 10.1101/2024.04.24.590626

Figure Lengend Snippet: A. Exogenous expression of HGF confers resistance to alectinib (25 mg/kg) in NSG xenografts. N=4 tumors for all groups except for HGF o/e control (N=2). Error bars represent SEM. B . Diagram of the experimental design to assess the impact of stromal activation of tumor cMET -mediated bypass signaling in vivo . C . Volumetric response dynamics of H3122 xenograft tumors in NSG and NSG hHGF hosts, continuously treated with 25 mg/kg alectinib or vehicle control. Error bars represent SEM; N= 4 & 18 for the control and alectinib-treated groups, respectively. D . Diagram of the experimental idea: cMET inhibition should suppress the enhanced relapse in NSG hHGF xenografts. E . Tumor response dynamics for vehicle control (N=4), 40 mg/kg capmatinib (N=4), 20 mg/kg alectinib (N=10) and alectinib/capmatinib (N=10) combination treated groups respectively. F . Representative images of anti-BrdU IHC from xenograft tumor tissues at the indicated time points. Arrows point to the examples of stromal regions defined by counterstain. P values in tumor growth analyses represents the significance of the interaction term of the repeated measurement 2-way ANOVA analyses between the indicated groups.

Article Snippet: The human HGF Antibody was purchased from R&D systems (AB-294-NA); murine HGF recombinant protein was purchased from Sino Biological (50038-MNAH-20).

Techniques: Expressing, Control, Activation Assay, In Vivo, Inhibition

Journal: bioRxiv

Article Title: Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators

doi: 10.1101/2024.04.24.590626

Figure Lengend Snippet: A . Impact of the indicated concentrations of human and murine HGF on the viability of H3122 and STE1 cells under 0.1µM alectinib. B . Tumor sizes (diameters) of xenograft tumors in NSG and NSG hHGF hosts pre-treatment. Each dot represents an individual tumor. C . Volumetric traces of individual parental and HGF expressing H3122 xenograft tumors treated with 25 mg/kg alectinib or vehicle control. C ) Volumetric traces of individual pH3122 xenograft tumors in NSG and NSG hHGF hosts treated with 25 mg/kg alectinib or vehicle control. D . Final tumor weights from the experiment depicted in C . E. Volumetric data of individual H3122 xenograft tumors treated with 40mg/kg capmatinib, 25 mg/kg alectinib or vehicle control in NSG (left panel) or NSG hHGF (right panel) hosts. F . Final tumor weights from the experiment depicted in E.

Article Snippet: The human HGF Antibody was purchased from R&D systems (AB-294-NA); murine HGF recombinant protein was purchased from Sino Biological (50038-MNAH-20).

Techniques: Expressing, Control